ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $4,266,350.00 in Stock

Posted by Brian Himes on May 13th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) CEO Nikhil Lalwani sold 55,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the transaction, the chief executive officer owned 349,889 shares in the company, valued at $27,140,889.73. This represents a 13.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

ANI Pharmaceuticals Trading Up 1.7%

ANIP traded up $1.38 during trading on Wednesday, reaching $80.88. 308,836 shares of the company’s stock were exchanged, compared to its average volume of 412,504. The company’s fifty day moving average price is $77.08 and its 200-day moving average price is $80.70. The firm has a market capitalization of $1.81 billion, a PE ratio of 20.48 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a fifty-two week low of $56.71 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period last year, the company earned $1.70 EPS. The firm’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ANIP shares. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $107.33.

Check Out Our Latest Analysis on ANI Pharmaceuticals

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $28,000. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. raised its stake in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 237 shares during the period. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals in the 4th quarter valued at about $48,000. Finally, State of Wyoming acquired a new stake in ANI Pharmaceuticals during the second quarter worth approximately $50,000. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.